Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.

ABSTRACT:

Background

There is an international epidemic of hepatitis C virus (HCV) infection among human immunodeficiency virus (HIV)-infected men who have sex with men. Sustained virologic response (SVR) rates with pegylated interferon and ribavirin treatment are higher in these men during acute HCV than during chronic HCV, but treatment is still lengthy and SVR rates are suboptimal.

Methods

We performed a pilot study of combination therapy with telaprevir, pegylated interferon, and ribavirin in acute genotype 1 HCV infection in HIV-infected men. Men who were treated prior to the availability of, or ineligible for, telaprevir were the comparator group. The primary endpoint was SVR12, defined as an HCV viral load <5 IU/mL at least 12 weeks after completing treatment.

Results

In

SUBMITTER: Fierer DS 

PROVIDER: S-EPMC3935497 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature